May. 13, 2015
Hutchison Medipharma announced on May 13, 2015 that it is set to receive a total of US$18 million in payments from Eli Lilly and Company (Lilly). The payments have been triggered by the positive results of the first proof-of-concept (POC) study for fruquintinib in the treatment of patients with metastatic colorectal cancer (mCRC) in China. Fruquintinib, a novel selective inhibitor of the Vascular Endothelial Growth Factor (VEGF) receptor tyrosine kinases, was discovered by HMP.